XNCR
Xencor Inc
NASDAQ · Healthcare · Biotechnology · US
$24.72
+0.53%Year over year
Reported trailing growth
- Revenue
- -36.1%
- EBITDA
- -14.3%
- EBIT
- -69.5%
- EPS
- +13.5%
- Free cash flow
- -47.9%
- Operating cash flow
- -53.4%
Forward estimates
Based on analyst estimates
- Revenue
- +12.6%
- EBITDA
- -57.0%
- EPS
- -39.9%
Three-year CAGR
- Revenue
- -8.6%
- EBITDA
- +74.8%
- EBIT
- +0.5%
- Net income
- +60.5%
- EPS
- +65.4%
- Free cash flow
- +33.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026